683 Capital Management’s Mereo BioPharma MREO Stock Holding History

683 Capital Management’s Portfolio MREO Stock Details MREO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.74M	Sell	11,777,856 -222,144	-2%	-$66.6K	0.18%	78
2026 Q1	$3.96M	Sell	12,000,000 -3,025,000	-20%	-$1.3M	0.21%	84
2025 Q4	$6.26M	Buy	15,025,000 +10,150,000	+208%	+$19.3M	0.27%	69
2025 Q3	$10M	Buy	4,875,000 +525,000	+12%	+$968K	0.52%	46
2025 Q2	$11.8M	Sell	4,350,000 -285,000	-6%	-$688K	0.77%	34
2025 Q1	$10.4M	Buy	4,635,000 +85,000	+2%	+$240K	0.72%	40
2024 Q4	$15.9M	Sell	4,550,000 -299,800	-6%	-$1.18M	0.99%	22
2024 Q3	$19.9M	Sell	4,849,800 -150,200	-3%	-$621K	1.52%	16
2024 Q2	$18M	Sell	5,000,000 -750,000	-13%	-$2.43M	1.36%	20
2024 Q1	$19M	Sell	5,750,000 -450,000	-7%	-$1.52M	1.39%	20
2023 Q4	$14.3M	Buy	6,200,000 +200,000	+3%	+$383K	1.17%	30
2023 Q3	$7.74M	Buy	6,000,000 +600,000	+11%	+$796K	0.6%	54
2023 Q2	$7.13M	Buy	5,400,000 +3,400,000	+170%	+$3.94M	0.51%	55
2023 Q1	$1.41M	Buy	2,000,000 +1,875,000	+1,500%	+$1.69M	0.11%	131
2022 Q4	$93.8K	Buy	+125,000	New	+$103K	0.01%	237

Other funds holding MREO

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

DCM

Defilade Capital Management Emeryville, California $747M AUM

Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return

Tejara Capital London, United Kingdom $243M AUM 9.84% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Ishara Investments Los Angeles, California $136M AUM

683 Capital Management's MREO Position: Q2 2026 in Review

683 Capital Management reduced its Mereo BioPharma (MREO) stake by 1.9% in Q2 2026, selling an estimated $66.6K and leaving 11,777,856 shares worth $3.74M. The position accounts for 0.18% of the portfolio, ranked #78.

683 Capital Management first reported a position in MREO in Q4 2022 and has held it in 15 quarters since. The position peaked at $19.9M in Q3 2024. 61 funds tracked by Wall St. Rank hold MREO as of Q2 2026.

683 Capital Management held 11,777,856 shares of Mereo BioPharma worth $3.74M as of Q2 2026.
683 Capital Management sold 222,144 Mereo BioPharma shares in Q2 2026, an estimated $66.6K.
Mereo BioPharma made up 0.18% of 683 Capital Management's portfolio in Q2 2026, its #78 holding.
683 Capital Management first reported a position in Mereo BioPharma in Q4 2022 and has held it in 15 quarters since.
683 Capital Management's Mereo BioPharma position peaked at $19.9M in Q3 2024.
61 funds tracked by Wall St. Rank held Mereo BioPharma as of Q2 2026.

Based on 683 Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.